papillary thyroid carcinoma specimens; paired normal tissues; adjacent normal tissues; tumor xenografts
HEK293; HEK293T; Nthy-ori3-1; TPC-1; SW579; FTC133; FTC113; MDA-T32; MDA-T120; XTC-1; KAT-5
cell line-derived xenograft
PI3K/AKT (promotes); MAPK (promotes); proliferation (promotes); migration (promotes); invasion (promotes); EMT (promotes); apoptosis (inhibits); ceRNA regulation (promotes)
RNase R Treatment; RT-qPCR; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Wound Healing Assay; Transwell Assay; TUNEL; IHC (Immunohistochemistry); Western Blot; In Vivo Animal Model; Bioinformatics Analysis
High expression was positively correlated with larger tumor size, advanced tumor stage, and lymph node metastasis; circ_0067934 might be a prognostic marker or therapeutic target for PTC treatment.
circ_0067934 is upregulated in papillary thyroid carcinoma tissues and cell lines and acts as an oncogenic circRNA. It promotes malignant phenotypes by sponging miR-1301-3p, increasing HMGB1 expression, and activating PI3K/Akt and MAPK signaling. High expression is associated with aggressive clinicopathological features, suggesting potential prognostic and therapeutic relevance.
0.8006
circ_0067934 promotes the progression of papillary thyroid carcinoma cells through miR-1301-3p/HMGB1 axis.
combined biological and clinical study